Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas
Saved in:
| Title: | Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas |
|---|---|
| Authors: | Izu Belloso, Rosa María, Gainza Apraiz, I., Ortiz Romero, Pablo Luis, Servitje Bedate, Octavio, Fernández de Misa Cabrera, Ricardo, Peñate, Yerai, Hernandez-machin, B., Estrach Panella, Ma. Teresa (María Teresa), Llamas Velasco, Mar, Yanguas Bayona, J. Ignacio, Morillo Andújar, Mercedes, Acebo Mariñas, Elvira, Pérez Gala, S., Armario Hita, J. C., Sánchez Sambucety, P., Ortiz Brugués, Ariadna, Eguren Michelena, C., Bielsa Marsol, Isabel, López Pestaña, A., Blanes Martínez, M. del Mar, Fernández Guarino, M., Lopez Lerma, Ingrid |
| Contributors: | Medicina, Institut Català de la Salut, [Izu-Belloso R, Gainza-Apraiz I] Hospital Universitario Basurto, Bilbao, Spain. [Ortiz-Romero P] Hospital 12 de Octubre, Madrid, Spain. [Servitje-Bedate O] Hospital de Bellvitge, Barcelona, Spain. [Fernández de Misa-Cabrera R] Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain. [Peñate Y] Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, Spain. [Lopez-Lerma I] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Source: | Actas Dermo-Sifiliograficas-2024, Vol. 115, n.6 pp. 1-8 RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz Universidad de Cádiz Actas Dermo-Sifiliograficas r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut instname Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Dipòsit Digital de la UB |
| Publisher Information: | Elsevier BV, 2024. |
| Publication Year: | 2024 |
| Subject Terms: | Mycosis fungoides, Male, Adult, Skin Neoplasms, S & eacute, Tetrahydronaphthalenes, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Cutaneous T-cell lymphoma, T cells, Medicaments antineoplàstics - Ús terapèutic, Mycosis Fungoides, Antineoplastic Combined Chemotherapy Protocols, Skin cancer, Humans, Sezary Syndrome, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, T-Cell::Lymphoma, T-Cell, Cutaneous, Càncer de pell, Aged, Retrospective Studies, Aged, 80 and over, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Middle Aged, Lymphoma, T-Cell, Cutaneous, 3. Good health, Pell - Càncer - Tractament, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Treatment Outcome, Cèl·lules T, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células T::linfoma cutáneo de células T, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Bexarotene, Spain, Sézary syndrome, Avaluació de resultats (Assistència sanitària), Retinoid, Female, zary syndrome, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents |
| Description: | Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL.This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals.A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported.Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL. |
| Document Type: | Article |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 0001-7310 |
| DOI: | 10.1016/j.ad.2023.12.007 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/38395224 https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11239 https://www.sciencedirect.com/science/article/pii/S0001731024003582?via=ihub https://hdl.handle.net/11351/11543 https://hdl.handle.net/2445/214598 http://hdl.handle.net/10498/33728 |
| Rights: | CC BY NC ND |
| Accession Number: | edsair.doi.dedup.....18e09e1734ec9fb5df18a639a7990174 |
| Database: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL.This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals.A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported.Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL. |
|---|---|
| ISSN: | 00017310 |
| DOI: | 10.1016/j.ad.2023.12.007 |